ABL1 is altered in 1.35% of esophageal carcinoma patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 3.34% of esophageal carcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

ARID1A is altered in 13.12% of esophageal carcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATM is altered in 3.87% of esophageal carcinoma patients [2].

ATM is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

ATR is altered in 2.97% of esophageal carcinoma patients [2].

ATR is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATR status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

ATRX is altered in 2.57% of esophageal carcinoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is altered in 1.66% of esophageal carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

BRAF is altered in 1.67% of esophageal carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 3 clinical trials for esophageal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [3].

BRCA1 is altered in 2.53% of esophageal carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

BRCA2 is altered in 5.35% of esophageal carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

BRIP1 is altered in 2.27% of esophageal carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

C11orf30 is altered in 0.62% of esophageal carcinoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCND1 is altered in 12.3% of esophageal carcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CCND2 is altered in 1.52% of esophageal carcinoma patients [2].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND2 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CCND3 is altered in 3.32% of esophageal carcinoma patients [2].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND3 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CCNE1 is altered in 7.26% of esophageal carcinoma patients [2].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CCNE2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE2 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK12 is altered in 7.92% of esophageal carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

CDK2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK4 is altered in 1.17% of esophageal carcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK4 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK6 is altered in 4.65% of esophageal carcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK6 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN1A is altered in 0.61% of esophageal carcinoma patients [2].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN1B is altered in 1.17% of esophageal carcinoma patients [2].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN2A is altered in 26.84% of esophageal carcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CHEK1 is altered in 0.72% of esophageal carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK1 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

CHEK2 is altered in 1.65% of esophageal carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

DDR2 is altered in 2.19% of esophageal carcinoma patients [2].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is altered in 8.33% of esophageal carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 16.67% of esophageal carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 7 clinical trials for esophageal carcinoma, of which 4 are open and 3 are closed. Of the trials that contain ERBB2 status and esophageal carcinoma as inclusion criteria, 2 are phase 1 (0 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].

Fam-trastuzumab deruxtecan has evidence of efficacy in patients with ERBB2 mutation in esophageal carcinoma [3].

ERBB4 is altered in 6.05% of esophageal carcinoma patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2 is altered in 2.22% of esophageal carcinoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC3 is altered in 0.78% of esophageal carcinoma patients [2].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC4 is altered in 2.04% of esophageal carcinoma patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC5 is altered in 1.16% of esophageal carcinoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC6 is altered in 1.98% of esophageal carcinoma patients [2].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCA is altered in 3.14% of esophageal carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCA status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCB is altered in 0.49% of esophageal carcinoma patients [2].

FANCB is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCB status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCC is altered in 1.19% of esophageal carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCC status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCD2 is altered in 2.15% of esophageal carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCD2 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCE is altered in 1.77% of esophageal carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCE status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCF is altered in 1.1% of esophageal carcinoma patients [2].

FANCF is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCF status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCG is altered in 1.53% of esophageal carcinoma patients [2].

FANCG is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCG status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCI is altered in 1.76% of esophageal carcinoma patients [2].

FANCI is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCI status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCL is altered in 1.83% of esophageal carcinoma patients [2].

FANCL is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCL status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FANCM is altered in 5.85% of esophageal carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCM status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

FGF19 is altered in 13.01% of esophageal carcinoma patients [2].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF19 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGF4 is altered in 12.75% of esophageal carcinoma patients [2].

FGF4 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF4 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGFR1 is altered in 2.92% of esophageal carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and esophageal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FGFR2 is altered in 3.39% of esophageal carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and esophageal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FLT1 is altered in 2.83% of esophageal carcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is altered in 3.23% of esophageal carcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is altered in 0.3% of esophageal carcinoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KDR is altered in 2.43% of esophageal carcinoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 1.21% of esophageal carcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is altered in 13.39% of esophageal carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 4 clinical trials for esophageal carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [3].

MAP2K1 is altered in 1.13% of esophageal carcinoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K2 is altered in 1.18% of esophageal carcinoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K3 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K3 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K4 is altered in 1.49% of esophageal carcinoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K5 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K5 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K6 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K6 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K7 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K7 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK1 is altered in 0.63% of esophageal carcinoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK3 is altered in 0.29% of esophageal carcinoma patients [2].

MAPK3 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK3 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MCPH1 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

MDM2 is altered in 3.51% of esophageal carcinoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM4 is altered in 0.71% of esophageal carcinoma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH1 is altered in 1.43% of esophageal carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH3 is altered in 0.44% of esophageal carcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MRE11A is altered in 1.46% of esophageal carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MRE11A status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

MSH2 is altered in 1.38% of esophageal carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH3 is altered in 0.37% of esophageal carcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH6 is altered in 2.53% of esophageal carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MUTYH is altered in 1.21% of esophageal carcinoma patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NBN is altered in 2.09% of esophageal carcinoma patients [2].

NBN is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

NPM1 is altered in 0.46% of esophageal carcinoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is altered in 2.0% of esophageal carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PALB2 is altered in 1.85% of esophageal carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

PARP1 is altered in 1.23% of esophageal carcinoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is altered in 1.3% of esophageal carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is altered in 2.12% of esophageal carcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 is altered in 1.77% of esophageal carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS2 is altered in 2.04% of esophageal carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLE is altered in 3.57% of esophageal carcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R1A is altered in 1.26% of esophageal carcinoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is altered in 2.48% of esophageal carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

RAD50 is altered in 1.72% of esophageal carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

RAD51 is altered in 0.95% of esophageal carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

RAD51B is altered in 0.14% of esophageal carcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

RAD51C is altered in 0.63% of esophageal carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

RAD51D is altered in 0.48% of esophageal carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

RAD54L is altered in 0.25% of esophageal carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

RAF1 is altered in 1.17% of esophageal carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RB1 is altered in 4.08% of esophageal carcinoma patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RET is altered in 2.49% of esophageal carcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is altered in 2.94% of esophageal carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SLX4 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

SMARCB1 is altered in 1.12% of esophageal carcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STAG2 is altered in 0.96% of esophageal carcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STK11 is altered in 1.78% of esophageal carcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TEK is altered in 1.63% of esophageal carcinoma patients [2].

TEK is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TNFRSF10B is altered in 0.49% of esophageal carcinoma patients [2].

TNFRSF10B is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF10B status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is altered in 81.26% of esophageal carcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA is altered in 4.33% of esophageal carcinoma patients [2].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC1 is altered in 0.49% of esophageal carcinoma patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].